Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $19.71.

ALT has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday. They issued a “buy” rating and a $18.00 price target on the stock. Finally, UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company.

Altimmune Stock Performance

ALT stock opened at $6.87 on Tuesday. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The company has a market capitalization of $488.63 million, a price-to-earnings ratio of -4.43 and a beta of 0.22. The business’s 50 day moving average price is $8.10 and its two-hundred day moving average price is $7.20.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter. During the same quarter last year, the company posted ($0.39) EPS. Sell-side analysts forecast that Altimmune will post -1.36 earnings per share for the current year.

Institutional Trading of Altimmune

Several institutional investors have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Altimmune by 12.9% during the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after purchasing an additional 2,687 shares in the last quarter. Virtu Financial LLC bought a new position in Altimmune during the 3rd quarter valued at about $674,000. Barclays PLC boosted its holdings in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after acquiring an additional 75,064 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after acquiring an additional 74,194 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Altimmune by 27.5% during the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after purchasing an additional 42,553 shares during the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.